Polyoxidonium
Adenocarcinoma
/ drug therapy
Adjuvants, Immunologic
/ therapeutic use
Adult
Aged
Breast Neoplasms
/ drug therapy
Cell Differentiation
/ drug effects
Chemotherapy, Adjuvant
/ methods
Dendritic Cells
/ drug effects
Female
Humans
Killer Cells, Natural
/ drug effects
Lymphocyte Activation
/ drug effects
Lymphocytes, Tumor-Infiltrating
/ drug effects
Middle Aged
Neoadjuvant Therapy
/ methods
Piperazines
/ therapeutic use
Polymers
/ therapeutic use
T-Lymphocytes, Cytotoxic
/ drug effects
T cell
aliphatic polyamines
breast cancer
cytotoxic lymphocyte
dendritic cells
natural killer cells
polyoxidinidum
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
07
2019
accepted:
01
11
2019
entrez:
19
12
2019
pubmed:
19
12
2019
medline:
11
11
2020
Statut:
epublish
Résumé
Immunotherapy, which is seen as a major tool for cancer treatment, requires, in some cases, the presence of several agents to maximize its effects. Adjuvants can enhance the effect of other agents. However, despite their long-time use, only a few adjuvants are licensed today, and their use in cancer treatment is rare. Azoximer bromide, marketed under the trade name Polyoxidonium® (PO), is a copolymer of N-oxidized 1,4-ethylenepiperazine and (N-carboxyethyl)-1,4-ethylene piperazinium bromide. It has been described as an immune adjuvant and immunomodulator that is clinically used with excellent tolerance. PO is used in the treatment and prophylaxis of diseases connected with damage to the immune system, and there is interest in testing it in antitumor therapy. We show here that PO treatment for 1 week induced positive pathological changes in 6 out of 20 patients with breast cancer, including complete response in a triple-negative patient. This correlated with an increased tumor CD4
Identifiants
pubmed: 31849934
doi: 10.3389/fimmu.2019.02693
pmc: PMC6892947
doi:
Substances chimiques
Adjuvants, Immunologic
0
Piperazines
0
Polymers
0
azoximer bromide
90G53638ZD
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2693Informations de copyright
Copyright © 2019 Alexia, Cren, Louis-Plence, Vo, El Ahmadi, Dufourcq-Lopez, Lu, Hernandez, Shamilov, Chernysheva, Vasilieva, Vorotnikov, Vishnevskay, Tupitsyn, Rossi and Villalba.
Références
Theranostics. 2018 Jun 14;8(14):3856-3869
pubmed: 30083264
Nat Immunol. 2012 Apr 18;13(5):439-47
pubmed: 22513334
J Exp Clin Cancer Res. 2019 Jun 19;38(1):268
pubmed: 31217020
Front Immunol. 2018 Aug 13;9:1869
pubmed: 30150991
Curr Opin HIV AIDS. 2010 Sep;5(5):409-13
pubmed: 20978382
Front Immunol. 2012 Jul 05;3:187
pubmed: 22783260
Blood. 2010 Aug 26;116(8):1299-307
pubmed: 20505160
Bull Exp Biol Med. 2000 Jul;130(7):701-4
pubmed: 11140591
PLoS One. 2016 Apr 21;11(4):e0150434
pubmed: 27100180
J Immunol. 2009 Feb 15;182(4):1972-81
pubmed: 19201850
J Immunother Cancer. 2018 Jul 9;6(1):67
pubmed: 29986768
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7000-4
pubmed: 2169617
Arch Physiol Biochem. 2012 Oct;118(4):197-203
pubmed: 22385273
Nat Rev Immunol. 2005 Jan;5(1):43-57
pubmed: 15630428
Oncoimmunology. 2015 Jan 09;4(3):e991613
pubmed: 25949911
EBioMedicine. 2015 Aug 13;2(10):1364-76
pubmed: 26629531
Int J Biochem Cell Biol. 2013 Jan;45(1):106-13
pubmed: 22568930
J Innate Immun. 2011;3(3):216-26
pubmed: 21454962
Onco Targets Ther. 2018 Aug 08;11:4673-4683
pubmed: 30122958
Oncoimmunology. 2017 Dec 20;7(4):e1409322
pubmed: 29632722
Contemp Clin Trials Commun. 2018 Aug 07;11:156-164
pubmed: 30112460
Int Immunopharmacol. 2004 Dec 15;4(13):1615-23
pubmed: 15454114
Clin Exp Vaccine Res. 2015 Jan;4(1):23-45
pubmed: 25648619
Front Immunol. 2013 Jul 31;4:214
pubmed: 23914187
Immunotherapy. 2018 Feb;10(2):131-137
pubmed: 29260620
Expert Rev Vaccines. 2018 Mar;17(3):207-215
pubmed: 29372660
Vopr Onkol. 1985;31(12):69-73
pubmed: 4082510
Blood. 2010 Nov 11;116(19):3865-74
pubmed: 20733159
Russ J Immunol. 2003 Apr;8(1):53-60
pubmed: 12717555
J Clin Oncol. 2008 Mar 10;26(8):1275-81
pubmed: 18250347
Int J Cancer. 2014 Jul 15;135(2):371-8
pubmed: 24921087
Front Immunol. 2016 Mar 03;7:66
pubmed: 26973646